Advancements in Protein based Nano Particulate system for treatment of Pulmonary Infections- A Review
Keywords:Pulmonary diseases, charge-mediated coacervation, advanced carrier system, nano particles, aerodynamic properties.
In addition to the so-called small molecule drugs, proteins and peptides are of increasing interest for
pharmacotherapy, due to several advantageous properties. In general, those compounds are administered parenterally. However, non-invasive routes of administration represent a great part of research. Amongst others is the pulmonary application of proteins and peptides for local delivery in the case of pulmonary diseases, such as idiopathic pulmonary fibrosis, where the alveolar epithelium is affected. To ensure an intracellular delivery, nano particles in a size range of 150 nm will be prepared via charge-mediated coacervation, characterized for their physicochemical properties and loaded with several model-proteins. The material used for nano particle preparation was chosen to be positively and negatively charged starch derivatives, which were synthesized from potato starch. Although nano particles in that size range are known to show an increased cell uptake, they do not show a high deposition in the deep lung. Thus, an advanced carrier system consisting of a fast dissolving micro particle matrix with embedded starch nano particles will be developed and characterized. Due to its aerodynamic properties, that carrier system must be able to deposit a high fraction of the applied dose in the deep lung (~50%), while at the same time demonstrating (in in vitro models) the ability to facilitate uptake of starch nano particles into cells of the alveolar epithelium after fast dissolution of the micro particle matrix.
C.Coester, P. Nayyar, and J.Samuel,“In vitro uptake of gelatin nano particles by murine dendritic cells and their intracellular localization European Journal of Pharmaceutics and Biopharmaceutics , 2006; 62(3): 306-314.
R. K. Verma and S. Garg, “Current status of drug delivery technologies and future directions,”Pharmaceutical Technology, vol.25,pp.1–14,2001.
Nanoparticles for drug delivery to the lungs. TRENDS in Biotechnology ,25:563–570. Finlay, W.H. (2005).
Gibaldi ’ s Drug Delivery Systems in Pharmaceutical Care. Bethesda, MD: American Society of Health System.
Labiris, N.R. and Dolovich, M.B. Pulmonary drug 5. delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol ., 2003;56 : 588–599.
Tena, A.F.; Clarà, P.C. Deposition of inhaled particles in the lungs. Arch Bronconeumol. 2012; 48(17): 240–246.
Yang, W.; Peters, J.I.; Williams, R.O. Inhaled nanoparticles—A current review. Int. J. Pharm. 2008;356(18): 239–247.
Patton, J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Deliv. Rev. 1996; 19: 3–36.
Patton, J.S.; Brain, J.D.; Davies, L.A.; Fiegel, J.; Gumbleton, M.; Kim, K.-J.; Sakagami, M.; Vanbever, R.; Ehrhardt, C. The particle has landed—Characterizing the fate of inhaled pharmaceuticals. J. Aerosol Med. Pulm. Drug Deliv. 2010;23:S71–S87.
Anderson, M.W., Orton, T.C., Pickett, R.D. and Eling, T.E. 7. Accumulation of amines in the isolated perfused rabbit lung. J Pharmacol Exp. Ther 1974;189 : 456–466.
11 D ollery, C.T. and Junod, A.F. Concentration of proponol in isolated, perfused rabbit lung. J. Pharmacol ,1976;57:67–71.
12 J orfeldt, L., Lewis, D.H., Lofstrom, J.B. and Post, C. Lung uptake of lidocaine in healthy volunteers. Acta Anaesth Scand , 1979;23 : 567–574.
R oerig, D.L., Kotrly, K.J., Dawson, C.A., Ahlf, S.B., 10. Gualtieri, J.F. and Kampine, J.P. First pass uptake of verapamil, diazepam and thiopental in the human lung. Anaesth Analg, 1989;69 : 461–466.
Suhara, T., Sudo, Y., Yoshida, K., Okubo, Y., Fukuda, 11. H., Obata, T., Yoshikawa, K., Suzuki, K. and Sasaki, Y. The limiting role of mucus in drug absorption: Drug permeation through mucus solution. Int J Pharm
Finlay, W.H. (2005). 2. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction . London: Academic Press.
Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Guenther, A.; Betz, T.; Bakowsky, U.; Seeger, W.; Kissel, T.; Gessler, T. Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomed. Nanotechnol. Biol. Med. 2011;7:341–350.
Varshosaz, J.; Ghaffari, S.; Mirshojaei, S.F.; Jafarian, A.; Atyabi, F.; Kobarfard, F.; Azarmi,
S. Biodistribution of amikacin solid lipid nanoparticles after pulmonary delivery. BioMed. Res. Int. 2013;2013: 1–8.
Menon, J.U.; Ravikumar, P.; Pise, A.; Gyawali, D.; Hsia, C.C.W.; Nguyen, K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomater. 2014, in press, doi:10.1016/j.actbio.2014.01.033
Beck-Broichsitter, M.; Ruppert, C.; Schmehl, T.; Günther, A.; Seeger, W. Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. Biochim. Biophys. Acta 2013; 1838:474–481.
Adler-Moore, J.; Proffitt, R.T. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother. 2002; 49: 21–30.
21 itt, C.G. (1990). Poly-ε caprolactone and its copolymers. In: Langer, R. (ed.), Biodegradable Polymers as Drug Delivery Systems . New York: Marcel Dekker, p. 71.
Shoyele, S.A. and Slowey, A. Prospects of formulating proteins/peptides as aerosols for pulmonary drug delivery. Int J.of Pharmaceutics
;314 : 1–8.
lbasarah, Y.Y., Somavarapu, S. and Taylor, K.M.Stabilizing protein formulations during air-jet nebulization. Int J Pharm , 2010;402 : 140–5.
Ahmad, Z. and Khuller, G.K. Alginate- based 70. sustained release drug delivery systems for tuberculosis. Expert Opin Drug Deliv, 2008; 5 : 1323–34.
Frasher, J.R.E., Laurent, T.C., Laurent, U.B.G. Hyaluronan: Its nature, distribution, functions and turnover. Journal of Internal Medicine, 1997; 242 : 27–33.
Kalalipour, M., Najafabadi, A.R., Gilani, K., Esmaily, 87. H. and Tajerzadeh, H. Effect of dimethylbeta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. J Pharm Sci, 2008;97 : 5176–85.
Bonacucina, G., Martelli, S. and Palmieri, G.F. Rheological, mucoadhesive and release properties of Carbopol gels in hydrophilic cosolvents. Int. J. Pharm , 2004;282: 115- 130.
Roberts RA, Shen T, Allen IC, Hasan W, DeSimone JM, Ting JPY. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. PLoS ONE. 2013; 8:e62115.doi: 10.1371/journal.pone.0062115
29 Mueller, R. Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art. Eur. J. Pharm. Biopharm. 2000;50:161–177.
Bunjes, H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 2010;62:1637–1645.
Bunjes, H. Structural properties of solid lipid based colloidal drug delivery systems. Curr. Opin. Colloid Interface Sci. 2011; 16: 405–411.
Bunjes, H.; Unhruh, T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv. Drug Deliv. Rev. 2007;59:379–402.
Scherließ, R. The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells. Int. J. Pharm. 2011; 411: 98–105.
Sakagami, M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv. Drug Deliv. Rev. 2006; 58:1030– 1060.
Foster, K.A.; Avery, M.L.; Yazdanian, M.; Audus, K.L. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 2000;208:1–11.
Arora, S.; Rajwade, J.M.; Paknikar, K.M. Nanotoxicology and in vitro studies: The need of the hour. Toxicol. Appl. Pharm. 2012;258:151– 165.
Martin, A.R., Thompson, R.B. and Finlay,
W.H. MRI 100. measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles . J Aerosol Med Pulm Drug Deliv,2008; 21 : 335–42
Kessinger, C.W., Peyton, M., Minna, J.D., Brown, K.C. and Gao, J. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm, 2010;7 : 32–40.
Hauluhn, J. and Rosenbruch, M. Inhalation toxicity 111. of propineb. Part I: Results of subacute inhalation exposure studies in rats. Inhal Toxicol , 2003;15 : 411–34.
Shvedova, A., Valerian, E.K. and Bengt, F. Close 116. encounters of the small kind: Adverse effects of man made material interfacing with the nano-cosmos of biological systems. Annu Rev Pharmacol Toxicol , 2010;50 : 63–88.
Tsytsikova, L. (2009). 118. Global List of Organizations and Efforts Related to Nanotechnology, Nanoscience, Nanomaterials, and Food and Agriculture Products. Available at: http://www.ilsi.org/NorthAmerica/Documents/F OOD%20CHEMICAL%20SAFETY/Global%20 List%20of%20 Organizations%20and%20Efforts%20Related%2 0to%20 Nanotechnology.pdf. Accessed on 18 March 2011.
Buttini, F.; Colombo, G.; Kwok, P.C.L.; Wui,
W.T. Chapter 6—Aerodynamic assessment for inhalation products: Fundamentals and current pharmacopoeial methods. In Inhalation Drug Delivery: Techniques and Products; John Wiley & Sons: Chichester, UK, 2013; pp. 91–119.
Brinkac, L.; Voorhies, A.; Gomez, A.; Nelson, K.E. The threat of antimicrobial resistance on the human microbiome. Microb. Ecol. 2017; 74:1001–1008.
Mejias, J.C.; Roy, K. In-vitro and in-vivo characterization of a multi-stage enzyme- responsive nanoparticle-in-microgel pulmonary drug delivery system. J. Control. Release 2019; 316:393–403.
Gaspar, R.; Duncan, R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 2009; 61:1220–1231.
How to Cite
Copyright (c) 2021 Asian Pacific Journal of Nursing and Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.